Last updated: January 27, 2026
Summary
Selpercatinib (brand name Retevmo) is a targeted cancer therapy developed by Eli Lilly and Company, designed to inhibit RET (rearranged during transfection) gene alterations. Approved for specific RET-altered cancers, it has gained prominence due to its efficacy in treating metastatic non-small cell lung cancer (NSCLC), thyroid cancers, and other RET-driven tumors. This report provides an in-depth review of recent clinical trial developments, evaluates the current market landscape, analyzes competitive positioning, and projects future growth based on ongoing studies and market trends.
Clinical Trials Update for Selpercatinib
Recent and Ongoing Significant Clinical Trials
| Trial ID |
Focus |
Phase |
Status |
Key Data / Outcomes |
Expected Completion |
| LIBRETTO-001 |
RET-mutant NSCLC, thyroid cancers, and other solid tumors |
Phase 1/2 |
Approved / Ongoing |
ORR (Objective Response Rate): 64% in NSCLC; 69% in RET fusion-positive thyroid cancers |
Completed (2021 results published) |
| LIBRETTO-431 |
RET fusion-positive NSCLC |
Phase 3 |
Enrolling |
Comparing Selpercatinib vs. standard chemo/immunotherapy |
Estimated completion: 2025 |
| LIBRETTO-531 |
RET-mutant medullary thyroid carcinoma (MTC) |
Phase 3 |
Ongoing |
Efficacy and safety data collection |
Estimated completion: 2023 |
| LIBRETTO-365 |
First-line treatment of RET fusion-positive NSCLC |
Phase 2 |
Ongoing |
Objective response data; progression-free survival (PFS) metrics |
Estimated completion: 2024 |
Key Clinical Findings
- Efficacy in RET-positive NSCLC: ORR of approximately 64% in previously treated patients, with durable responses noted over 12 months.
- Thyroid Cancers: Demonstrated ORRs exceeding 69% in RET fusion-positive thyroid malignancies, with acceptable safety profiles.
- Safety Profile: Common adverse events include hypertension, diarrhea, dry mouth, and elevated liver enzymes. Serious adverse events are relatively rare.
Latest Approvals and Label Updates
- FDA Approval: September 2020, for metastatic RET fusion-positive NSCLC, RET MTC, and RET rearranged advanced or metastatic thyroid cancers.
- EMA and Other Markets: Ongoing data submissions and evaluations are aligned with FDA approval, with market authorizations anticipated in 2023–2024.
Market Analysis of Selpercatinib
Market Size and Segments
| Segment |
Patient Population Estimate (2023) |
Market Value (USD, 2023) |
Growth Rate (CAGR, 2023–2028) |
| RET Fusion-positive NSCLC |
~25,000 globally |
$1.8 billion |
15% |
| RET-Mutant Thyroid Cancers |
~7,000 globally |
$0.7 billion |
12% |
| RET-Altered Other Cancers |
~3,000 |
$0.3 billion |
10% |
Assumptions: Incidence rates collated from GLOBOCAN (2022) and market reports [1].
Competitive Landscape
| Competitor |
Drug Name |
Indications |
Approval Status |
Market Share (2023) |
Key Differentiator |
| Eli Lilly |
Retevmo (Selpercatinib) |
RET-altered cancers |
Approved (FDA, EMA) |
~85% (initial launch) |
First RET-specific TKI |
| Approved/Investigational |
Pralsetinib (GAVRETO) |
RET-altered NSCLC, thyroid |
Approved (FDA, EMA for certain indications) |
~10% |
Similar mechanism, different safety profile |
| Other |
LOXO-292 (Pralsetinib) |
Under clinical evaluation |
Approved in the US |
N/A |
Competitive options in pipeline |
Note: Selpercatinib's early market dominance attributed to first-mover advantage and favorable efficacy data.
Key Market Drivers
- Unmet Medical Need: RET alterations are found in approximately 1–2% of NSCLC and 10–20% of medullary thyroid carcinomas (MTC).
- Regulatory Approvals: Accelerated approvals in major markets facilitate market entry.
- Precision Medicine Trends: Rising adoption of NGS testing to identify RET alterations.
- Treatment Landscape Shifts: Evolving standards favor targeted therapies over chemotherapy or immunotherapy alone in RET-positive cancers.
Barriers to Market Growth
- Pricing and Reimbursement Challenges: Negotiations with payers may impact sales.
- Emerging Competition: Dual therapies targeting RET and co-altered pathways could erode margins.
- Limited Indication Expansion: Current approvals cover narrow indications; broader use hinges on ongoing trial success.
Market Projection & Growth Outlook (2023–2028)
| Year |
Estimated Global Market Value (USD) |
CAGR |
Key Factors Influencing Growth |
| 2023 |
$2.8 billion |
— |
Launch uptake; initial indications |
| 2024 |
$3.4 billion |
14% |
Expansion to first-line therapy, label updates |
| 2025 |
$4.1 billion |
15% |
Approval for additional indications; increased NGS testing |
| 2026 |
$4.9 billion |
13% |
Competitive stabilization, market penetration |
| 2027 |
$5.8 billion |
12% |
Combo therapies and broader label |
| 2028 |
$6.8 billion |
12% |
Continued pipeline success, increased awareness |
Sources: MarketWatch, GlobalData, Frost & Sullivan, combined expert analysis [2].
Competitive Dynamics and Strategic Opportunities
Strengths of Selpercatinib
- First-in-class status with rapid regulatory approval.
- Demonstrated high ORR and durable responses.
- Favorable safety profile compared to older TKIs.
Weaknesses & Risks
- Market exclusivity limited to current indications.
- Resistance mechanisms may limit long-term efficacy.
- Competition from pralsetinib and emerging agents.
Opportunities
- Approval in additional tumor types with RET involvement.
- Combination therapies incorporating Selpercatinib.
- Companion diagnostics enabling broader testing.
Threats
- Patent expirations and biosimilar development.
- Rapidly evolving targeted therapy landscape.
- Regulatory delays or restrictions in emerging markets.
Deep Dive: Regulatory and Policy Considerations
- FDA Accelerated Approval: Utilized due to compelling early data; mandates confirmatory trials.
- Pricing Policies: Cost-effectiveness assessments impacting reimbursement, notably across Europe.
- Guidelines Inclusion: Incorporation into NCCN and ESMO guidelines will accelerate adoption.
- Diagnostics Requirements: Reimbursement for molecular testing crucial for market penetration.
FAQs
Q1: What are the primary indications for Selpercatinib?
A1: FDA-approved for RET fusion-positive NSCLC, RET-mutant medullary thyroid carcinoma, and RET fusion-positive thyroid cancers.
Q2: How does Selpercatinib's efficacy compare to similar drugs?
A2: It demonstrates a higher ORR (~64%) in NSCLC than prior broader chemotherapies, with durable responses. Pralsetinib (GAVRETO) offers similar efficacy, with comparative safety profiles.
Q3: What ongoing trials could expand Selpercatinib's labeled indications?
A3: LIBRETTO-531 (RET-mutant MTC) and LIBRETTO-365 (first-line NSCLC) are pivotal for potential label expansion.
Q4: What are the key safety concerns associated with Selpercatinib?
A4: Common adverse effects include hypertension, diarrhea, dry mouth, elevated liver enzymes; serious adverse events are infrequent.
Q5: How is the market for Selpercatinib expected to evolve globally?
A5: Significant growth driven by expanding indications, increasing molecular testing, and evolving treatment guidelines; targeted at ~$6.8 billion globally by 2028.
Key Takeaways
- First-mover advantage positions Selpercatinib as a leading RET inhibitor, with robust efficacy data and regulatory approval in key markets.
- Market expansion hinges on successful completion of ongoing trials, broader labeling, and adoption in clinical practice.
- Competitive landscape is intensifying with pralsetinib and other pipeline drugs; differentiation via safety, efficacy, and diagnostics remains critical.
- Pricing and reimbursement policies significantly influence market penetration, especially in Europe and emerging economies.
- Future potential includes combination therapies, broader indications, and integration into personalized oncology workflows.
References
[1] Globocan 2022. International Agency for Research on Cancer.
[2] MarketWatch, GlobalData, Frost & Sullivan reports (2023).
